Search clinical trials for: olodaterol (BI 1744) low

Total 86 results

Boehringer Ingelheim

Completed

A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

Asthma

Austria, Germany, Poland, Romania, Slovakia, Slovenia
Boehringer Ingelheim

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II

Pulmonary Disease, Chronic Obstructive

Austria, Belgium, Canada, Germany, Russian Federation
Boehringer Ingelheim

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

Pulmonary Disease, Chronic Obstructive

Australia, Austria, Canada, France, Germany
Boehringer Ingelheim

Completed

Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Canada, Germany, Netherlands, Sweden
Boehringer Ingelheim

Completed

Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Liver Diseases | Healthy
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD

Pulmonary Disease, Chronic Obstructive

Japan
Boehringer Ingelheim

Completed

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Investigation of the Metabolism and Pharmacokinetics of [14C]BI 1744 CL and [14C]BI 1744 CL Administered as an Oral Solution in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

12 / 48 wk Pivotal PFT vs PBO in COPD II

Pulmonary Disease, Chronic Obstructive

United States, China, Germany, Taiwan
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma

Asthma

United States, Canada, France, Germany
Boehringer Ingelheim

Completed

Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Single Rising Peroral Doses of BI 1744 CL in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD

Pulmonary Disease, Chronic Obstructive

Belgium, Netherlands
Boehringer Ingelheim

Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Terminated

Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II

Pulmonary Disease, Chronic Obstructive

Argentina, Brazil, Canada, Czech Republic, Denmark, Finland, Germany, Hong Kong, India, Italy, Korea, Republic of, Malaysia, Norway, Philippines, Romania, Russian Federation, South Africa, Spain, Sweden, Thailand
Boehringer Ingelheim

Completed

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I

Pulmonary Disease, Chronic Obstructive

Argentina, Brazil, Canada, Croatia, Czech Republic, Denmark, Finland, Germany, Hong Kong, India, Italy, Korea, Republic of, Malaysia, Norway, Philippines, South Africa, Spain, Sweden, Thailand, Ukraine
Boehringer Ingelheim

Completed

Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body

Healthy

Belgium
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma

Asthma

United States, Austria, Germany, Hungary, Slovakia, Slovenia
Boehringer Ingelheim

Completed

BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis

Pulmonary Disease, Chronic Obstructive

Germany
AbbVie
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Psoriasis

United States, Germany, United Kingdom
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Germany
Boehringer Ingelheim

Completed

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Canada, Finland, France, Germany, Hungary, Italy, Spain, United Kingdom
Boehringer Ingelheim

Completed

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Belgium, Denmark, Germany, Hungary
Boehringer Ingelheim

Completed

Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

Hepatitis C

Japan
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Japan, Korea, Republic of, Malaysia and more
Boehringer Ingelheim

Completed

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Germany, Netherlands, Norway
Boehringer Ingelheim

Completed

Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Hepatitis C, Chronic

France, Germany, Switzerland
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.

Pulmonary Disease, Chronic Obstructive

Japan
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.

Pulmonary Disease, Chronic Obstructive | Asthma

United States, Canada, Germany, Netherlands
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Spain, Sweden, Taiwan
Boehringer Ingelheim

Completed

Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

Hepatitis C | Pharmacokinetics

Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Denmark, France, Ireland, Korea, Republic of, Portugal, United Kingdom

3

Subscribe